Trial Outcomes & Findings for Low Dose Ketamine Infusion for Analgesia in the Emergency Department to Reduce Side Effects (NCT NCT05518877)

Recruited subjects from December 2022 to April 2025 at the Emergency Department at Akron City Hospital.

Race and Ethnicity were not collected from any participant.

The Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) is a clinician administered tool used to evaluate acute side effects associated with ketamine infusion. The composite scale is a measure of the effects including fatigue, dizziness, headache, feeling of unreality, hearing, vision, or mood changes, generalized discomfort, and hallucinations. The SERSDA composite score is the mean overall score of nine adverse events on a scale of 0 (no adverse effect) to 36 (very bothersome effect).

The visual analog scale is a validated, patient reported subjective measure for acute and chronic pain intensity. The sale consists of a 10cm (100mm) horizontal line anchored by "no pain" (0) and "worst imaginable pain" (10). Participants indicate their level by marking a point on the line. The score is quantified in millimeters from the "no pain" anchor, with higher values indicating greater pain severity.

The Richmond Agitation-Sedation Scale (RASS) is a validated, clinician administered tool used to assess a patient's level of arousal, agitation, or sedation. The scale ranges from +4 (combative) to 0 (alert and calm) to -5 (unarousable) allowing standardized characterization of agitation and sedation states. Higher positive scores indicate increasing agitation, while more negative scores indicate deeper levels of sedation.